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ABSTRACT 
 
Background: The observation that fetuses with chromosomal abnormalities often have 
excess fluid at the back of their neck at gestational weeks 10 – 14 dates back to the early 
1990s. Since then increased nuchal translucency (NT) has been used as a screening method 
for fetal aneuploidies. Increased NT is also associated with a wide variety of structural 
defects and genetic syndromes. Adverse outcomes become more likely by increasing NT. 
Long-term studies with a large cohort about the neurodevelopmental outcome of euploid 
children with increased fetal NT are sparse and the neurodevelopment is worth further 
study. There are controversial results about the effect of fetal gender in the NT.  
Aims: The primary aim of this study is to collect data on the pregnancy outcomes, long-
term neurodevelopmental and overall outcomes in a large cohort of fetuses with increased 
NT from singleton pregnancies in order to improve parental counselling. The secondary aim 
is to detect whether the gender of the fetus has an impact on the outcome when the NT is 
increased. 
Subjects and methods: All singleton pregnancies referred to the Department of Fetal 
Medicine (DFM) at the Helsinki University Hospital (HUH) due to increased NT in the 
first-trimester screening during 2002 – 2007 were studied. The pregnancy outcome data 
were retrieved from hospital databases. Pregnancy outcome was defined adverse if there 
was an abnormal karyotype, structural defect, genetic syndrome, or if the pregnancy ended 
in miscarriage (MC), termination of pregnancy (TOP), or perinatal death. When assessing 
the pregnancy outcome, the health of the newborn was followed until discharge from the 
delivery hospital. In order to find out the long-term neurodevelopmental and long-term 
overall outcomes, data of the children born from this cohort were retrieved from several 
national registers. All data implicating health problems were checked from the individual 
medical charts. The gender impact on pregnancy outcomes and the long-term outcomes 
were analyzed.  
Results: There were 1063 fetuses with increased NT in the first-trimester screening. 
Abnormal karyotype was observed in 224 fetuses (21%) and adverse pregnancy outcome 
occurred in 322 (30%). TOP was performed in 209 (20%) and there were 43 (4%) MCs (n 
= 36) and perinatal deaths (n = 7). Of the 834 euploid fetuses 74 (9%) had structural defects 
or genetic disorders. Favourable pregnancy outcome became less likely by increasing NT:  
favourable outcome occurred in 92% in the lowest NT group (95th percentile – 3.4 mm) and 
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in 18% in the highest NT group (≥ 6.5 mm). Of the euploid fetuses with normal second-
trimester ultrasound (US) examination 96% were healthy at the discharge from the delivery 
hospital. Neurodevelopmental outcome was assessed in 691 euploid children. 
Neurodevelopmental impairment was detected in 29 (4.2%) and it was severe in 12 (1.7%). 
During the follow-up time (mean 6.5 years) of the euploid children with increased NT in 
the first-trimester screening but normal findings in the second-trimester US screening 
(n=733), major structural defects, severe neurodevelopmental impairment, or genetic 
disorders were detected in 54 cases (7%). There was no difference in the outcomes between 
the genders among the euploid fetuses. In the total cohort, male fetuses had better pregnancy 
outcomes than females (p = 0.049). This was due to the higher percentage of aneuploidies 
among the females compared to the males (p = 0.04).  
Conclusions: One in five fetuses with increased NT (≥ 95th percentile) has chromosomal 
abnormalities and one in ten of the euploid fetuses has structural defects or genetic 
syndromes. Major health impairment (major structural defect, severe neurodevelopmental 
impairment, or genetic syndrome) is likely to be detected in 7% of euploid children with 
increased NT in the first-trimester screening but normal findings in the second-trimester 
screening. These results are helpful in counselling the parents when increased NT is 
detected.    
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1 INTRODUCTION 
 
Two-dimensional US examination was introduced in obstetrics in the 1960s (Donald 1965). 
In the beginning, due to low resolution and the lack of grey scale image, this technique 
could only be used to estimate the number of fetuses, the presenting part, and the estimation 
of gestational age from the biparietal diameter. Since then the enormous development of 
the technique has led to the possibility of early prenatal diagnosis of even small structural 
defects.  
Fetal screening for aneuploidies is a common practice in the developed countries. First-
trimester US examination is part of the screening including NT thickness measurement of 
the fetus. Besides NT, the vitality, number, location, and gross anatomy of the fetus is 
determined. NT is an ultrasonographically visible translucent space at the back of the fetal 
neck (Figure 1) (Nicolaides et al. 1992; Wilson, Venir & Farquharson 1992). Some NT is 
visible in virtually all fetuses at 10 to 14 weeks of pregnancy, and after 14 gestational weeks 
it usually vanishes (Pajkrt et al. 1995). Increased NT is known to be associated with 
chromosomal and structural defects, genetic syndromes, and adverse pregnancy outcome 
(Kagan et al. 2006; Nicolaides, Brizot & Snijders 1994; Souka et al. 2001). Favourable 
pregnancy outcome becomes less likely by increasing NT (Bilardo et al.  2007; Souka et al. 
2001). 
 
Figure 1. Increased nuchal translucency of 3.1mm at the back of the fetal neck is visible as a translucent area. 
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Parental counselling follows a positive screening result. Parents are offered further 
diagnostic work-up to detect aneuploidies and structural defects. An abnormal finding in 
fetal screening raises anxiety in the parents (Chueh et al. 2007; Kleinveld et al. 2006; 
Kowalcek et al. 2003), although most of the screen positives will have a normal diagnostic 
result. Parents need to make difficult decisions based on the information they are offered. 
These decisions include invasive procedures chorionic villus sampling (CVS) or 
amniocentesis (AC) for karyotyping, carrying a small risk of MC, and if the fetus is 
diagnosed with chromosomal abnormalities, the decision of continuing or terminating the 
pregnancy. There is a need for accurate and clear counselling before the diagnostic work-
up and after the result, even if it is normal. A prerequisite for adequate counselling is high-
quality screening and subsequent studies about the outcomes after a positive screening 
result. 
Although increased NT has been studied since the end of the 1980s, studies of the long-
term neurodevelopmental or overall outcome of children born after increased fetal NT with 
a large cohort are sparse. Additionally, studies of fetal gender impact on NT have been 
controversial. The aim of this study is to gather high-quality data of Finnish pregnancies of 
a large number of fetuses with increased NT. By recording the pregnancy outcomes and the 
long-term outcomes of children born after increased fetal NT, we aim to produce additional 
data to improve parental counselling in such cases.  
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2 REVIEW OF THE LITERATURE 
 
2.1 Screening 
 
2.1.1 General 
 
Screening refers to a systematic attempt to find, from an apparently healthy population, 
people at high enough risk of a specific condition to warrant further action. Most screening 
tests serve only to mark the condition and are not diagnostic as such. Screen positives are 
offered further diagnostic work-up, impossible to be offered to the whole population due to 
financial resources or the possible harmful effects, or both. The results of screening can be 
divided into four different groups: false and true positives and false and true negatives. In 
most cases those who have obtained positive markers in screening achieve normal test 
results in the further diagnostic work-up. This is the group of false positives. Those 
diagnosed with the condition screened for form the group of true positives. Those who failed 
to be marked in spite of the condition screened for are the false negatives; true negatives 
are those who do not have the condition screened for and obtain a negative result in the 
screening. The ability to correctly detect the individuals with the condition, i.e. the true 
positives, is called sensitivity. Specificity is the ability to correctly detect the individuals 
without the condition, i.e. the true negatives. Positive predictive value signifies the 
likelihood that an individual who obtains a positive screening result actually has the 
condition screened for (Figure 2). 
 
Figure 2. Sensitivity = A/A+C, Specificity = D/B+D, Positive predictive value = A/A+B 
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There are several general demands for a pathological condition to be suitable for screening. 
They have been stated by the World Health Organization in the 10 principles of screening 
(Wilson & Jungner 1968) and in the criteria for screening by the Danish Council of Ethics 
(The Danish Council of ethics 2000): 
- The condition is significant both to an individual and society. 
- It is possible to observe the condition by screening before it would naturally 
appear. 
- The prevalence of the condition is (relatively) high and the condition is severe. 
- The condition and its natural course are well known and it has a precursor or a 
pre-stage. There is an accepted treatment at this stage. 
- It is clear how the screening test and the diagnostic work-up are interpreted and 
who is treated. 
- There is a cost effective screening tool, which is fast, generally accepted, and 
does not carry a high risk or harm the participants. 
- There is a diagnostic tool, which is available and generally accepted.  
- There is a cure for the condition or the true positives benefit from the earlier 
diagnosis of the condition. 
- The specificity and the sensitivity of the screening are high enough and the 
effectiveness of the screening is estimated. 
- The social and ethical effects of the screening and the effects of a false positive 
and false negative test results have been evaluated. 
- The costs of the screening are known and they are in proportion with the health 
care service resources.  
- The screening organization is well described. 
- Screening is continuous.  
 
If the screening test is dichotomic (e.g. positive blood in feces), it is easy to define the result 
as positive or negative. If the screening test is a continuous variable, there is a cut-off point 
to separate the screen positives from the screen negatives. If the screening test is a 
combination of several independent tests, a mathematic model is needed for individual risk 
estimation.  Several different issues are considered when the cut-off point between screen 
positives and screen negatives is defined. If the test is very sensitive, almost all individuals 
with the condition are detected. Unfortunately, usually when the sensitivity rises, the 
specificity decreases. This means that more individuals without the condition end up with 
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a positive screening result and more diagnostic tests are required. These false positives 
cause extra cost, raise unnecessary anxiety, and predispose healthy individuals to the risks 
of the diagnostic test. Thus the severity of the condition, the cost and the risk of the 
diagnostic test, and financial resources need to be considered when determining the cut-off 
point. Usually some kind of compromise is decided upon, as screening should produce 
enough health benefits to be justified from the perspective of public health. 
Participating in screening is voluntary, and it is of great importance that the individuals 
attending screening understand the sensitivity and the specificity, what a positive or a 
negative screening result means, what the diagnostic tests are, and what possible treatments 
the condition screened for may need. This is not an easy task, since many screenings are 
complex and the information should be understandable to all possible participants. Different 
kinds of problems are encountered depending on the type of screening. On the one hand, 
preventing cervical cancer by pap-smear screening for example, is an almost perfect method 
for screening in many ways, but the main problem is how to make women attend the 
screening.  On the other hand, fetal first-trimester screening for trisomy 21 is well attended, 
but it is difficult to make sure that women attending the screening understand the correct 
meaning of possibly getting a positive screening result and the decisions they need to make 
thereafter. 
 
2.1.2 Fetal first-trimester screening   
 
The main goal of first-trimester screening is to find fetuses with trisomy 21, which is the 
most common aneuploidy. The concept of screening for trisomy 21 was introduced in the 
late 1960s, when laboratory techniques for fetal karyotype determination were developed 
(Nadler 1968; Nadler & Gerbie 1970). Fetuses at a risk for other aneuploidies, some of 
which are phenotypically more severe than trisomy 21, are also detected by the same 
screening tests (Breathnach et al. 2007; Ekelund et al. 2011; Engelbrechtsen et al. 2013; 
Kagan et al. 2006; Loane et al. 2013; Torring et al. 2015). Structural defects are detected in 
the screening strategies including US examination (Souka & Nicolaides 1997, Whitlow et 
al. 1999). Several first-trimester screening strategies have been developed since the 1970s: 
screening by maternal age, screening by NT, combined screening, and non-invasive 
prenatal testing (NIPT). Each new screening strategy has a better performance compared to 
the older ones. The method of choice at present is still combined screening, although NIPT 
carries high expectations in the future but is still too expensive to be used as the general 
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method of screening. Different strategies of contingent screening have been introduced and 
are being studied. Since US examination is part of the combined and NT screening, the 
vitality, number, size, and gross anatomy of the fetus are determined in addition to the risk 
estimation for trisomy 21.  
 
2.1.2.1 Screening by maternal age 
The correlation of advancing maternal age and trisomy 21 was noted already in 1876, when 
a detailed description of 62 patients with Down syndrome was published (Fraser & Mitchell 
1876). The incidence of trisomies increases by increasing maternal age (Antonarakis 1991; 
Hook 1981; Loane et al. 2013; Pandya et al. 1995; Savva, Walker & Morris 2010). Table 1 
shows the risk of trisomy 21 by maternal age according to a recent Finnish study (Marttala 
et al. 2010). Offering karyotyping for mothers over certain age is the oldest fetal screening 
strategy. In the 1990s, it was estimated that if mothers over 37 years of age were offered 
karyotyping, the detection rate for trisomy 21 would be about 30% with a 5% invasive 
testing rate (Snijders et al. 1996). As the trend after the 1990s has been towards advancing 
maternal age, using 37 years as a cut-off would nowadays result in a higher intake than 5%, 
since at 2012 - 2013 already 19.7% of all deliveries in Finland were to mothers ≥ 35 years 
of age (THL 2014) and 11% of deliveries in Finland were to mothers ≥ 37 years of age 
(personal information from the birth register, THL). A similar trend can be verified in all 
Europe (Loane et al. 2013). 
 
 
 
 
 
 
 
 
 
2.1.2.2 Screening by nuchal translucency thickness 
In the early 1990s NT was shown to be applicable as a screening tool for fetal aneuploidies 
(Nicolaides et al. 1992; Savoldelli et al. 1993). At first fixed cut-off points, such as 3 mm 
Table 1. The risk of trisomy 21 (terminations and newborns) in different maternal 
age groups according to a Finnish study (Marttala et al. 2010). 
Maternal age (years) Risk of trisomy 21 
< 20 1:746 
20 - 24 1:1140 
25 - 29 1:862 
30 - 34 1:566 
35 - 39 1:172 
40 - 44 1:49 
≥ 45 1:23 
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or 3.5 mm, were used. Soon, however, gestational age-dependent cut-off points were 
recommended, since the NT increases by increasing fetal size from nine to 14 gestational 
weeks (Pajkrt et al. 1995), and using such cut-off points reduces the number of false positive 
test results. It was also recommended that each center performing screening by NT 
measurement should have its own reference values (Pajkrt et al. 1995). Usually in NT 
screening information about maternal age is combined with the information about the NT 
thickness and an individual risk number is calculated. Fixed or gestational age dependent 
cut-off points are also used. NT screening detects about 75% of trisomic pregnancies with 
a 5% false positive rate (Gasiorek-Wiens et al. 2001; Pandya et al. 1995b; Schwarzler et al. 
1999; Snijders et al. 1998; Zoppi et al. 2001), but the sensitivity of NT screening has varied 
form 62% (Taipale et al. 1997) up to 91% (Theodoropoulos et al. 1998). 
 
2.1.2.3 Combined screening 
In combined screening levels of pregnancy-associated protein A (PAPP-A) and free human 
chorion gonadotropin β unit (β-hCG) in the maternal serum, fetal NT, and maternal age are 
considered in a risk calculation. This method detects 80 - 90% of trisomy 21 fetuses with a 
false positive rate of 5% (Ekelund et al. 2015; Kagan et al. 2008; Kagan et al. 2009c; 
Nicolaides et al. 2005; Rozenberg et al. 2006; Spencer et al. 1999; Wald et al. 2003). In 
pregnancies affected by trisomy 21 the PAPP-A levels are lower and the β-hCG levels 
higher than in pregnancies with a normal fetus (Spencer et al. 1999). Several different 
strategies in producing combined screening have been developed. The serum tests can be 
taken before NT measurement, achieving the highest accuracy at 9-10 weeks of pregnancy 
(Kirkegaard et al. 2008; Wright et al. 2010), or at the same time as the NT measurement 
(one-stop combined screening OSCAR) (Kagan et al. 2008; Spencer et al. 2000a). Taking 
the serum tests earlier in the pregnancy gives slightly better screening performance 
compared to serum testing at the same time as NT measurement (detection rates 95% and 
92%, respectively) (Ekelund et al. 2012), but as the detection rate of trisomy 21 from one-
stop clinics has been reported to be as good as 90% with a 5% false positive rate (Bindra et 
al. 2002; Spencer et al. 2003) both strategies are used. 
 
2.1.2.4 Noninvasive Prenatal Testing (NIPT) 
Cell-free fetal deoxyribonucleic acid (DNA) is present in maternal plasma (Lo et al. 1997). 
The amount increases by increasing gestation and may be observed as early as seven weeks 
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of gestation (Lo et al. 1998). NIPT is a fairly new technique where cell-free fetal DNA is 
analyzed from the maternal blood sample. It is highly specific (99%) and highly sensitive 
(99.9%) in detecting trisomy 21, and the specificity for detecting trisomies 13 and 18 is also 
good: 91% and 96%, respectively (Gil et al. 2015). Most common trisomies and aberrations 
of sex-chromosomes can be screened by NIPT (Alberti et al. 2015; Liang et al. 2013; 
Porreco et al. 2014; Verweij et al. 2013; Zhang et al. 2015). The positive predictive value 
of NIPT in general population (81%) is markedly better than that of the combined screening 
(3%) (Norton et al. 2015). Unfortunately this technique is still rather expensive and thus not 
available for general screening (Conner, Gustafsson & Kublicas 2015; Cuckle, Benn & 
Pergament 2013). Since some false positive test results have been reported (Dugo et al. 
2014), NIPT cannot serve as a diagnostic test and a positive NIPT result must be confirmed 
by invasive testing of the fetal karyotype by CVS or AC. 
 
2.1.2.5 Contingent screening 
Contingent screening combines different strategies of screening with maternal serum 
markers, US examination with different markers, and NIPT by offering further testing to 
only those with an intermediate (1:50 - 1:1000) and/or high risk (≥ 1:50) for aneuploidies. 
In the newest models, aiming at a better performance with low invasive testing rate and 
reasonable cost, karyotyping is offered to mothers at high risk and NIPT to women with an 
intermediate risk (Conner, Gustafsson & Kublicas 2015; Ekelund et al. 2012; Kagan et al. 
2010; Munoz-Cortes et al. 2012; Nicolaides et al. 2013; Sahota et al. 2010). 
 
2.1.2.6 Ultrasound markers for chromosomal abnormalities  
There are several US markers in addition to NT at the time of the first-trimester scan 
connected with chromosomal abnormalities. Recent publications suggest that the detection 
rate may be significantly increased up to 92 - 100% by adding them to US screening. 
(Ghaffari et al. 2012; Hsiao et al. 2014; Karadzov-Orlic et al. 2012). These US markers 
include the assessment of fetal nasal bone and blood flow measurements in the ductus 
venosus and the tricuspid valve. The nasal bone is absent in approximately 60% of cases 
with trisomy 21 versus 2.6% of euploid fetuses (Kagan et al. 2009a & 2010) and tricuspid 
regurgitation and reverse a-wave in ductus venosus are present in 65% and 55% of fetuses 
with trisomy 21 versus 3.2 and 0.9% of euploid fetuses, respectively (Kagan et al. 2009b & 
2010; Mula et al. 2015). The use of these US markers varies largely between the institutions.  
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2.1.3 Ethical aspects of fetal screening 
 
There are several aspects in fetal screening that may lead to ethical problems (Committee 
on Ethics and Genetics ACOG 2008). Screening for aneuploidies does not fulfill all criteria 
for a good screening target. Aneuploidies are common enough and in most cases severe 
enough to justify screening, but there is no treatment for the condition. The diagnostic test 
carries a small risk of MC of a healthy fetus due to a false positive screening result. The 
parents receiving a positive screening result first need to decide about the invasive testing 
and secondly, in the case of positive diagnostic test, they need to decide whether to continue 
the pregnancy or terminate it. Decision of TOP is an extreme ethical challenge (Choi, van 
Riper & Thoyre 2012; Jotkowitz & Zivotofsky 2010; Learman et al. 2005; Natoli et al. 
2012; Norton, Nakawaga & Kuppermann 2014). Several studies show that not all parents 
attending fetal screening are sufficiently aware of the method to make an informed decision 
whether to participate (Bangsgaard & Tabor 2013; Dahl et al. 2006; Farrell, Nutter & 
Agatisa 2011; Jaques, Halliday & Bell 2004; Santalahti et al. 1998; Ternby et al. 2015). 
Furthermore, many parents understand the screening as a part of routine antenatal care 
(Kobelka et al. 2009; Santalahti et al. 1999). Even if the screening result is positive, not all 
parents opt for invasive procedures (Kobelka et al 2009), which might reflect that the 
parents have not fully understood the information. High demands should be set to the 
information delivered to the parents before their decision to attend the screening.  
Offering screening for chromosomal abnormalities and structural defects implicates that 
TOP for these reasons is accepted and cost effective. This may have social consequences to 
the attitudes towards disabled people. On the one hand, fetal screening can make the 
disabled feel not accepted in society and screening may even be understood as threatening 
to human rights. On the other hand, fetal screening improves the autonomy of the expecting 
parents (Caplan 2015). The risk of chromosomal abnormalities increases by maternal age. 
The possibility of fetal screening might encourage some women of advanced age to become 
pregnant.  
Screening might reveal structural abnormalities, the clinical relevance of which is not 
known until the child is born. Such findings cause parental anxiety and might affect the 
pregnancy psychologically and disturb the emotional attachment to the unborn child. 
Chromosomal analysis might also reveal an abnormal result of which the prognosis and 
phenotype are difficult to interpret in the perinatal period, like mosaicisms, marker-
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chromosomes, rare translocations, or variants of unknown significance if chromosomal 
microarray is used. False negative test results might cause bitter feelings in the parents. A 
negative screening test result is often falsely interpreted as a promise of a healthy child and 
the correct meaning of a negative screening test result is not understood (de Jong & de Wert 
2015).   
A positive screening result poses some problems in every screening. Expecting mothers are 
especially vulnerable and a positive screening result is likely to raise anxiety (Allison et al. 
2011; Chueh et al. 2007; Kleinveld et al. 2006; Kobelka et al. 2009; Kowalcek et al. 2003; 
Marteau et al. 1992). The decision of whether to proceed with invasive testing carrying a 
risk of MC causes mental stress (Durand et al. 2010). However, the anxiety levels decrease 
after appropriate counselling (Tercyak et al. 2001) and return to normal after a normal 
diagnostic result (Allison et al. 2011; Chueh et al. 2007; Kleinveld et al. 2006). According 
to a recently published study, there is no additional residual anxiety after a positive 
screening test has been proven to be false-positive (Lou et al. 2015).  
 
 
 2.1.4 Screening and parental counselling  
 
Prenatal counselling is very important for alleviating anxiety (Tercyak et al. 2001). 
Attending fetal screening is voluntary. Informed consent is requested and it should be based 
on an informed decision. Both pre- and post-screening counselling should provide 
objective, precise, and thorough information. In fetal screening for aneuploidies, the 
algorithm is complex and the methods are not easily understood, since the individual risk is 
calculated by a combination of background information (age) and test results (NT, maternal 
serum markers). Fetal screening is discussed among other issues about pregnancy at the 
antenatal clinics, and it is possible that parents assume that participating in fetal screening 
for chromosomal abnormalities is part of the routine antenatal care (Kobelka et al. 2009; 
Santalahti et al. 1999). It is of essential importance to inform the parents about the voluntary 
nature of the prenatal screening. Those who decide against it should be reassured about 
equal pregnancy care. The information should be easily understandable and include a 
description of the conditions that screening is supposed to reveal. Since the time frame in 
fetal screening is limited, it is possible that the information is not always well comprehended 
in time for scheduling the tests.  
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The aims of prenatal counselling about increased risk for a genetic condition are to provide 
pre-test information as well as psychosocial support and assistance in decision making 
(Cohn et al. 1996). Ideal counselling should be nondirective i.e. the genetic counselor must 
respect the client’s right of autonomous decision. The goal of nondirectiveness is value-
neutral communication. Providing nondirective counselling is challenging but it is a 
worthwhile goal. Parents’ decisions are based on several different factors and it is important 
that these personal values and beliefs are listened to (Choi, van Riper & Thoyre 2012). More 
important than strict nondirectiveness or value-neutrality is that the facts are presented in a 
comprehensible and meaningful context to the parents (Anderson 1999; Kobelka et al 2009; 
Rentmeester 2001). The counselor has succeeded, if the parents reach a decision that is right 
for them and with which they feel satisfied.  
 
2.1.5 Fetal screening in Finland  
 
A working group on screenings was set in 2003 by the Ministry of Social Affairs and Health 
in Finland. One of its tasks is to re-evaluate the existing health-care screening programs and 
propose directions for the future. 
The Health Care Act in Finland (Health Care Act 339/2011) states that local authorities are 
in charge of organizing screenings according to the national screening programs. The 
present statutory prenatal group of screenings was introduced in 2008 including general US 
examination during early pregnancy, screening for aneuploidies, and later US examination 
screening for major structural abnormalities.  
The first-trimester screening for trisomy 21 is offered to all women attending the antenatal 
care clinics in Finland. Screening is voluntary and free of charge. The free-of-charge 
national antenatal clinics provide the information about the screening both orally and in 
written documents. At the HUH district, fetal first-trimester screening and second-trimester 
US screening were offered to all pregnant women registered at the antenatal clinics already 
prior to introduction of the Health Care Act. The current screening method at HUH is 
presented in Figure 3. 
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Figure 3. Current fetal screening protocol at Helsinki University Hospital -district. N, normal result; A, 
abnormal result.  
 
 
 
TOP is legal in Finland under certain circumstances (Laki raskauden keskeyttämisestä 
24.3.1970/239, ´The law of terminating pregnancy`). It is allowed up to 12+0 gestational 
weeks for social indications. This requires examination and consideration of two authorized 
physicians. From 12+1 to 20+0 gestational weeks TOP is possible when there are exceptional 
social indications or there is a reason to believe that the fetus has or is going to develop a 
severe developmental handicap, illness, or defect. The permission must be applied for from 
the National Supervisory Authority of Welfare and Health. From 20+1 to 24+0 gestational 
weeks TOP is possible only in cases with a definite diagnosis of severely affected fetus and 
it is applied from the same National Authority.  
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2.2 Chromosomal abnormalities  
 
2.2.1 Definition and terminology 
 
Human cells normally contain 46 chromosomes. Chromosomes are numbered, and each 
chromosome has a pair, of which one is inherited from the mother and the other from the 
father. Each cell has this diploid chromosomal count except for the gametes (the egg and 
the sperm), which are haploid and have 23 chromosomes. Sex chromosomes are XY in a 
male and XX in a female. A normal chromosome count is called euploid and marked either 
46,XY or 46,XX. Full aneuploidy is a pathological condition, where the chromosome 
number is not normal. Trisomy is the most common aneuploidy where there is one excess 
chromosome. The most common trisomy in humans is 16-trisomy. These fetuses, however, 
are miscarried in the early pregnancy and thus not detected in screening (Hassold et al. 
1995; Ljunger et al. 2005). The most common trisomies that survive to birth are trisomies 
21, 18, and 13. The karyotype is marked for example 47,XY+21 in a male trisomy 21. In 
polyploidy there are more than two of the whole chromosome sets. In triploidy there are 
three instead of two whole chromosome sets, and it is marked e.g. 69XXX. In partial 
aneuploidy the number of chromosomes is normal, but the genetic material is either reduced 
or increased (deletions, duplications, and unbalanced translocations). Structural alterations 
are also possible when the number of choromosomes and the amount of genetic material 
are normal. They may influence the function of the genes (balanced translocations, 
inversions). Full aneuploidies are usually caused by nondisjunction during meiosis in the 
gametes. The frequency of full aneuploidies increases by increasing maternal age, since 
errors in meiosis occur more often in the ageing gametes (Antonarakis 1991). Partial 
aneuploidies are often caused by errors in the homologous recombination (the exchange of 
genetic material between the matching parts of the chromosomes) which happens in normal 
meiosis. Translocations can be balanced or unbalanced. Balanced translocations usually do 
not affect the phenotype, but in meiosis they can lead to the formation of an unbalanced 
gamete and cause an unbalanced translocation in the next generation. Mosaicism means that 
the same individual has both normal cell lines and abnormal cell lines.  
Chromosomes contain genes, which are made of basepairs (bp). The whole human genome 
was mapped at 2001 (Mc Phersson et al. 2001). The size of the whole human genome is 
approximately 3 billion bps, one gene being from a few hundred bps to a few million bps. 
 23 
A chromosome contains few hundred - few thousand genes and the size of a chromosome 
is 33 million - 250 billion bps. (Gardner, Sutherland & Shaffer 2011; Richards & Hawley 
2011; Sweet & Michaels 2011).  
 
2.2.2 Prenatal chromosomal analysis 
 
The most common ways to obtain fetal cells for chromosomal analysis are CVS and AC, 
which both require an invasive procedure and carry a small risk of MC.  The first genetic 
AC was reported in 1956 (Fuchs & Riis 1956) and the first US guided CVS in 1984 (Smidt-
Jensen & Hahnemann 1984). CVS can be taken from 10 gestational weeks and AC from 14 
weeks on. Sometimes CVS is not technically possible, for example, in the case of posterior 
placenta in a retroverted uterus. Although the procedure-related risk of fetal loss has 
generally been considered to be approximately 0.5 - 1% (Alfirevic, Sundberg & Brigham  
2003; Tabor et al. 1986), the latest publications show lower figures of 0.06 - 0.1% for AC 
and 0.2 % for CVS (Akolekar et al. 2015; Eddleman et al. 2006) or even no increased 
procedure-related risk (Wulff et al. 2016). It has been shown that experience reduces the 
procedure related loss rate (Tabor, Vestergaard & Lidegaard 2009; Verjaal, Leschot & 
Treffers 1981).  
In CVS the specimen is placental tissue, which is a rich source of DNA since the 
cytotrophoblasts are rapidly duplicating cells and a substantial amount of DNA is received 
in the sampling. The CVS does not necessarily require culturing since the mitotic activity 
is high. In AC the cells are from the fetal skin, lungs, bladder, and the amnion. The mitotic 
activity is not as rapid as in the placental tissue. Cells need to be cultured before analysis, 
which takes approximately 14 days.  
Conventional karyotyping with G-banding became the gold standard in detecting 
chromosomal abnormalities in the 1970s. In this method the cell cycle is stopped at mitosis, 
the chromosomes are stained and examined microscopically and the size, shape, and 
number of chromosomes are analyzed. Aneuploidies and large (5-10Mbp) deletions, 
duplications, translocations, and inversions are diagnosed (Caspersson et al. 1970; Steele & 
Breg 1966). It is possible to detect the most common trisomies rapidly, in one to two days 
without culturing by using the rapid fluorescence in situ hybridization (FISH) (Ward et al. 
1993) or quantitative fluorescent polymerase chain reaction (QF-PCR) (Pertl et al. 1994) 
instead of conventional karyotyping (Hulten et al 2003). By using fluorescently labeled 
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probes in FISH or by measuring the quantities of chromosome specific short tandem repeats 
in QF-PCR, it is possible to diagnose 21-, 18-, 13- trisomies and differences in the number 
of sex chromosomes. The results are received faster, which is anxiety relieving for the 
parents (Leung et al. 2008), but other chromosomal abnormalities than trisomy 21, 18, 13, 
and sex-chromosome number variations  are not detected by these rapid techniques (Caine 
et al. 2005; Gekas et al. 2011). The disadvantage of the CVS is the possibility of obtaining 
placental mosaicism as a result in 1-2% of samples (Hahnemann & Vejerslev 1997). In 
cases where placental mosaicism is suspected, the fetal karyotype is confirmed by AC, 
which usually contains cells of the fetus only.  
Smaller (up to 400Kbp) submicroscopic, genetic changes are detected from the DNA by 
chromosomal microarray, which also has a short turn-around-time. There are two types of 
microarrays: array comparative genomic hybridization (aCGH) and single nucleotide 
polymorphism -array. Duplicated or deleted sections of DNA are called copy number 
variants (CNVs).  They can be pathologic, benign, or of unknown significance. Another 
type of DNA alteration is single nucleotide polymorphism where only a single nucleotide 
is altered. Both microarray methods detect CNVs and trisomies, but aCGH is not capable 
of detecting triploidy or balanced translocations (Gardner, Sutherland & Shaffer 2011). In 
a large study of 4282 prenatal DNA samples, additional 6% of pathologic CNVs were 
detected by microarray compared to conventional karyotyping in fetuses with structural 
defects diagnosed by ultrasonography. In fetuses with no structural defects the microarray 
found 1.6% additional pathologic CNVs compared to conventional karyotyping (Wapner et 
al. 2012). Up to 20% of pathological CNVs were found when samples from mentally 
retarded persons with normal conventional karyotyping results were analyzed by aCGH 
(Siggberg et al. 2010). In the parental counselling CNVs of unknown significance are 
challenging (Mikhaelian et al. 2013), but the number of uncertain CNVs is decreasing due 
to accumulating clinical experience and international networking.  
 
2.2.3 Trisomy 21 
 
The vast majority, approximately 95%, of trisomy 21 cases (Down syndrome) are caused 
by nondisjunction in meiosis of the gametes (90% of maternal origin) and classified as 
regular or standard. The rest of 21 trisomies include isochromosome 21, unbalanced 
translocations involving the chromosome 21, or mosaics. If trisomy 21 is caused by parental 
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translocation, the translocation is usually balanced in the parent, but inherited as unbalanced 
to the child.  
The incidence of trisomy 21 is approximately 22-27/10000 pregnancies (TOPs, MCs, 
intrauterine fetal demises (IUFDs), and liveborns) and 11-13/10000 liveborns (Loane et al. 
2013; Marttala et al. 2010; Morris & Alberman 2009). There are more males than females 
with trisomy 21, with a ratio 1.23:1 (Gardner, Sutherland & Shaffer 2011). 
Trisomy 21 is associated with fetal losses, congenital heart defects (CHDs), structural 
defects of the gastrointestinal organs and limb defects (Morris et al. 2014). Affected persons 
have typical dysmorphic features (broad flat face, slanting eyes, epicanthic eyefolds, and 
short nose), short stature, their motor skills develop slowly, they are prone to infections, 
and have mental retardation of various degrees (Harper 2010). 
 
2.2.4 Trisomy 18 
 
The prevalence of trisomy 18 (Edward syndrome) is approximately 5-6/10000 pregnancies 
(TOPs, MCs, IUFDs, and liveborns) and 1- 2.7/10000 liveborns (Loane et al. 2013; Savva, 
Walker & Morris 2010; Tonks et al. 2013,). Common features are CHDs, spina bifida, 
structural anomalies of the central nervous system, omphalocele, and rocker bottom foot. 
Approximately 80% of trisomy 18 fetuses have increased NT in the first-trimester US 
screening (Sherod et al. 1997; Yang et al. 2005). Most of the pregnancies end in MC, TOP, 
or IUFD (Morris & Savva 2008). Fetuses are small for their gestational age and often born 
prematurely. Most of the liveborns die soon after birth and only few survive beyond one 
year of age. All affected are mentally severely retarded (Rasmussen et al. 2003). 
 
2.2.5 Trisomy 13 
 
The prevalence of trisomy 13 (Patau syndrome) is approximately 2/10000 pregnancies 
(TOPs, MCs, IUFDs, and liveborns) and 0.5-1.6 /10000 liveborns (Ekelund et al. 2011; 
Loane et al. 2013; Savva, Walker & Morris 2010; Tonks et al. 2013). Common features are 
holoprosencephaly, CHDs, gastrointestinal and vesicourinary malformations, facial clefts, 
microftalmy, and polydactyly. Approximately 70% of fetuses with trisomy 13 have 
increased NT in the first-trimester US screening (Snijders et al. 1999). Most pregnancies 
end in MC, TOP, or IUFD (Morris & Savva 2008). All affected rare survivors are mentally 
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retarded. The syndrome is usually lethal and liveborns die soon after birth (Rasmussen et 
al. 2003). 
 
2.2.6 Other common chromosomal abnormalities 
 
Sex-chromosome abnormalities are clinically less severe than those of other chromosomes. 
The commonest sex-chromosome abnormality in males is 47,XXY (Klinefelter syndrome). 
The prevalence among liveborn is approximately 17/10000 (Morris et al. 2008). Clinical 
features include reduced fertility, gynecomastia, small testicles, and tall stature (Giltay & 
Maiburg 2010). The commonest sex-chromosome abnormality in females is 45,X (Turner 
syndrome). It is the only monosomy of liveborns in humans. The prevalence among 
liveborns is approximately 3/10000 (Gravholt et al. 1996). Most, up to 99% (Hook 1978), 
of the fetuses having 45,X are miscarried or IUFD occurs later in pregnancy (Ranke & 
Saenger 2001). Fetuses with Turner syndrome often present with extremely thick NT or 
cystic hygroma (Pinsker 2012). Clinical features of the survivors are aortic coarctation, 
premature ovarian failure, thick neck, and shortness (Ranke & Saenger 2001).  
 
2.3 Nuchal translucency  
 
2.3.1 Background 
 
NT is a fluid-filled collection at the back of the fetal neck. It is visible by US as a translucent 
area between the skin outline and the underlying soft tissues (Figure 1). In 1987 nuchal fold 
(thickening of the fetal neck in the late second trimester) was noticed to have an association 
with trisomy 21 in fetuses over 16 weeks of gestation (Benacerraf, Gelmon & Frigoletto 
1987). In the early 1990s, first trimester CVS was becoming more popular in the UK among 
women over 35 years of age. Nicolaides et al. observed, while sampling the placenta, that 
some of the fetuses were hydropic and had an excess of fluid at the back of the neck. They 
called this accumulation of fluid NT. They reported that 35% of fetuses with NT of 3 - 8 
mm had chromosomal abnormalities compared to 1%, when the NT was < 3mm (Nicolaides 
et al. 1992). At the same time other observations of the same kind were made (Wilson, 
Venir & Farquharson 1992). 
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Some NT is detected in all fetuses at 10 to 14 weeks of gestation. There is physiologic 
variation in NT thickness among normal fetuses and the thickness increases by increasing 
fetal size from 10 to 14 weeks (Braithwaite et al. 1996; Pajkrt et al. 1995; Wald et al. 2003). 
This is why it is important to use cut-off levels taking the fetal size into account rather than 
fixed cut-off levels. After 14 weeks the NT usually vanishes and in a fetus over 14 weeks 
nuchal fold is associated with an increased trisomy 21 risk (Agathokleus et al. 2013). About 
72% of fetuses with trisomy 21 have NT thickness above the 95th percentile, compared to 
4% of the euploid fetuses (Snijders et al 1998). 
 
2.3.2 Etiology 
 
The physiological background of the accumulation of extra fluid at the back of the fetal 
neck is not known. There are several hypotheses about the pathogenesis of this phenomenon 
and given the phenotypic heterogeneity of conditions associated with increased NT, a single 
cause is unlikely.  
 
Possible etiologies include the following: 
1.  Lymph overproduction, failure or delayed maturation of the lymphatic system 
(Gittenberger-De Groot et al. 2004; Haak et al. 2002; van der Putte & van 
Limborgh 1980) which has been demonstrated among fetuses with Turner 
syndrome (von Kaisenberg, Nicolaides & Brand-Saberi 1999), other 
chromosomal abnormalities (Miyabara et al. 1989), and fetuses with altered 
movement (Hyett et al. 1997b). 
2. Hemodynamic readjustment during cardiac development and cardiac 
dysfunction. Doppler studies of trisomic fetuses with increased NT have shown 
an abnormal flow in the ductus venosus and tricuspid regurgitation (Matias et 
al. 1999; Montenegro et al. 1997; Mula et al. 2015). Molecular studies of such 
fetuses’ cardiac tissue have shown increased levels of atrial and B-type 
natriuretic peptide mRNA (Hyett et al. 1996b). In pathological examination of 
chromosomally normal fetuses with increased NT, abnormalities of the heart 
and/or great arteries were found in 19/21 of cases. The most common finding 
was narrowing of the aortic isthmus (Hyett et al. 1996a). These findings support 
the theory of cardiac dysfunction.  However, in other studies of cardiac function 
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no difference between fetuses with increased and normal NT could be noticed 
(Haak et al. 2005; Huggon et al. 2004; Simpson & Sharland 2000). In one study 
signs of diastolic cardiac dysfunction were detected in fetuses with trisomy 21, 
but it could not be verified in those with isolated increased NT; this finding 
suggests that there are different etiologies causing the increased NT in different 
conditions (Mula et al. 2015). 
3. Alteration in the composition of the extracellular matrix (von Kaisenberg et al. 
1998a; von Kaisenberg et al. 1998b). CVS samples of euploid fetuses with 
increased NT showed underexpression of several genes including genes of 
embryonic development, extracellular matrix, vessel formation and 
differentation (Farina et al. 2006). 
4. Pressure and venous congestion in diaphragmatic hernia and skeletal dysplasias 
with narrowing of the chest (Sebire et al. 1997b; Spaggiari, Stirnemann & Ville 
2012). 
5. Accelerated growth of the fetus and delayed maturation of the cardiac system, 
which have been thought to be related to the thicker NT in normal male fetuses 
compared to the females (Prefumo, Venturini & de Biasio 2003; Timmerman, 
Pajkrt & Bilardo 2009).  
6. Fetal anemia or hypoproteinemia (Lam et al. 1999). 
 
Screening for perinatal infections is not warranted in pregnancies with increased NT (Sebire 
et al. 1997a). 
 
2.3.3 Measurement  
 
2.3.3.1 Correct technique 
An accurate NT image acquisition and appropriate training of professionals involved in the 
first-trimester screening are essential for a good screening performance. NT is measured in 
the mid-sagittal section. The image is zoomed until the fetal head and upper trunk occupy 
at least 75% of the screen. Fetal skin and amnion are distinguished from each other by fetal 
movements (Nicolaides 2004). The measurement is preferred at the fetal head in flexed 
position (Whitlow, Chatzipapas & Economides 1998), although the position does not make 
a big difference in the value (de Graaf et al. 2000). The calipers are placed correctly “on-
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to-on” instead of “on-to-out” (Figure 4) (Herman et al. 2000). More than one measurement 
are taken and the largest is used in the risk assessment (Nicolaides et al. 1992).  
 
         
Figure 4. Correct placement of the calipers “on-to-on” (A), incorrect placement (B, C). 
 
2.3.3.2 Timing 
The NT-measurement should be performed at 10 to 14 weeks of gestation (fetal crown-
rump length from 45 mm to 84 mm); before and after this time point the measurement fails 
more often. The recommended measurement time is at 12-13 weeks of gestation. At earlier 
gestation the fetal anatomical survey is not as accurate (6% success of anatomical 
visualization at 10 weeks vs. 96-98% at 12-13 weeks). Beyond 14 weeks the NT 
measurement becomes less accurate (98% success at 13 weeks vs 90% at 14 weeks). 
(Whitlow & Economides 1998; Mulvey et al. 2002). 
 
2.3.3.3 Operator variability 
Intra-observer variability in the first-trimester NT assessment has been shown to be < 0.70 
mm and inter-observer variability < 0.88 mm in 95% of cases, and repeatability was not 
related to the NT thickness (Pajkrt et al. 2000; Pandya et al. 1995a). The caliper placement 
repeatability was < 0.58 mm in 95% of the cases and it was concluded that the intra- and 
interobserver variability could largely be caused by the variability in the caliper placement 
(Pandya et al. 1995a). 
 
 30 
2.3.3.4 Education of sonographers 
Any test is only as good as the persons performing the measurements, and therefore formal 
and structured education should be provided to screeners, as it gives the basis for a 
functional and reliable NT measurement. It has been demonstrated that the intra- and 
interobserver variability is higher among unexperienced sonographers compared to 
experienced professionals (Pajkrt et al. 2000). One study showed that the ability to obtain a 
good NT-measurement improved by experience of more than 400 NT measurements (Wald 
et al. 2003), and another demonstrated that good quality was reached after 80 - 100 
measurements (Braithwaite, Morris & Economides 1996). Auditing the sonographers with 
personal feedback is compulsory in the quality control of NT measurements (Herman et al. 
1998; Snijders et al. 2002). 
 
2.3.3.5 Equipment 
Obtaining satisfactory images is possible only with good-quality US equipment. The effect 
of the machine quality is independent of the experience of the screener (Wald et al. 2003). 
Both transabdominal and transvaginal probes are used in NT measurement. Transvaginal 
route is used whenever transabdominal screening does not yield satisfactory image quality 
(e.g. in obese patients). The need for transvaginal route decreases by increasing gestational 
age (100% at 10 weeks vs 11% at 14 weeks) (Whitlow & Economides 1998; Mulvey et al. 
2002). 
A study exploring different machine-probe combinations showed that the variability of 
different combinations was greater than the intraobserver variability, but no difference was 
found between the transabdominal and transvaginal probes (Axell et al. 2014). The study 
was performed using a phantom, which does not take maternal characteristics (obesity, 
tissue density, uterine tilt) into account. First-trimester anatomic survey was showed best 
performance using the combination of transabdominal and transvaginal probes (Rossi & 
Prefumo 2013).  
 
2.3.3.6 Safety 
Diagnostic US is a form of energy that has possible effects on tissues. The acoustic waves 
are transformed to thermal and mechanical energy (heating, cavitation, and radiation 
pressure). Cavitation is not an issue in obstetric US since the fetus does not contain any gas, 
which is needed for cavitation to occur. Thermal Index (TI) and mechanical index (MI) are 
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used to quantify the output of medical US systems. (Bigelow et al. 2011). Hyperthermia is 
considered teratogenic (Graham, Edwards & Edwards 1998) and thus tissue heating due to 
US examination and its possible effects in the fetus need to be discussed. The thermal index 
(TI) represents the reasonable worst-case estimate of the temperature rise resulting from 
exposure to US examination. The higher the TI, the higher the potential temperature rise. 
TIbone (TIb) should be used after 10 weeks of gestation. TIb < 0.5 can be used for extended 
time, TIb of 0.5 - 1.0 for 30 minutes, and TIb ≥ 2.5 should be used only for less than one 
minute (Nelson et al. 2009). The TIb levels in US examination for NT-measurement without 
Doppler US were very low (0.2) (Sheiner & Abramowicz 2009). The TI is higher in Doppler 
US compared to B-mode sonography (Sheiner E & Abramowicz JS 2012). The “As Low as 
Reasonably Achievable” ALARA principle should be followed in all US examinations 
during pregnancy; this means that the total duration of scanning is minimized at the lowest 
possible acoustic output (American College of Obstetricians and Gynecologists 2009). 
 
2.3.3.7 Expressing nuchal translucency 
Fetal NT can be expressed in millimeters, but since the normal NT increases by increasing 
gestational age, it does not reflect the deviation from the normal median for a given crown-
rump length measurement. There are two ways to quantify the deviation of the measured 
NT from the normal median NT: delta NT and NT Multiples of Median (MoM) (Biagiotti 
et al. 1997). Delta NT is calculated by subtracting the normal median NT for the CRL-value 
from the measured value and expressing the deviation in millimeters. NT MoM is calculated 
by dividing the measured NT by the normal median NT for the CRL-value (Schuchter et al. 
1998). NT MoM 1.6 and delta NT 1 mm are approximately the same as the 95th centile NT 
value and NT MoM 2.0 and delta NT 1.5 mm are approximately the same as the 99th centile 
NT value (Maymon et al. 2004). The most recent modification is a mixture model for 
expressing fetal NT. The study that presented this model demonstrated that the NT of 
euploid fetuses increases by increasing gestational age in 95% of cases but only in 5% of 
fetuses with trisomy 21. The mixture model takes these gestation-dependent and gestation-
independent distributions into account. (Wright et al. 2008). 
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2.3.4 Abnormal findings in fetuses with increased nuchal translucency  
 
2.3.4.1 Chromosomal abnormalities 
Increased NT is associated with chromosomal abnormalities, mostly trisomy 21. The 
sensitivity of NT-screening with 95th centile cut-off reaches 75% with a false-positive rate 
of 5%, and the prevalence of chromosomal abnormalities increases by increasing NT 
thickness (Kagan et al. 2006; Pandya et al. 1995; Snijders et al. 1998). The percentage of 
chromosomal abnormalities in fetuses with NT ≥ 95th percentile – 3.5mm is 7% (Kagan et 
al. 2006) and in fetuses with NT ≥ 6.5mm 65-70% (Kagan et al. 2006; Snijders et al. 1998). 
In general, approximately 20% of fetuses with NT ≥ 95th percentile have an abnormal 
karyotype (Kagan et al. 2006; Mangione et al. 2001; Pandya et al. 1995), and half of the 
aneuploid fetuses with increased NT have trisomy 21. Other common chromosomal 
abnormalities among fetuses with increased NT are trisomies 13 and 18 and sex-
chromosome abnormalities 45,X (Turner syndrome) and 47,XXY (Klinefelter syndrome), 
and triploidy (Kagan et al. 2006; Pandya et al. 1995). The distribution of NT is different for 
each type of abnormal karyotype: fetuses with trisomy 21 usually have NT < 4.5mm, 
whereas the majority of fetuses with trisomy 13 and 18 have NT 4.5 – 8.4 mm, and fetuses 
with Turner syndrome typically have very thick NT, ≥ 8.5mm (Malone et al. 2005; Kagan 
et al. 2006; Wright et al. 2008).  
 
2.3.4.2 Structural defects 
Structural defects among euploid fetuses with increased NT have been verified in 
approximately 4% at birth in large studies (Pandya et al. 1995; Souka et al. 2001). However, 
the prevalence of such anomalies during pregnancy is higher, approximately 7 - 13% due 
to TOPs, MCs, and IUFDs (Bilardo et al. 1998; Souka et al. 2001; van Vugt, Tinnemans & 
van Zalen-Sprock 1998). The incidence of structural defects increases by increasing NT 
(Baer et al. 2014; Bilardo et al. 2007; Souka et al. 1998; Souka et al. 2001). CHDs comprise 
the majority of the structural defects associated with increased NT, followed by 
diaphragmatic hernia, pulmonary, genitourinary, musculoskeletal, and mid-line defects 
(e.g. exomphalos, cleft lip and palatum) (Baer et al. 2014; Pandya et al. 1995; Sebire et al. 
1997b; Souka et al. 1998 & 2001; Timmerman et al. 2010). The detection rates of different 
structural defects at the time of first-trimester screening varies from 100% (acrania, 
anencephaly, ectopia cordis, encephalocele) to 0% (e.g. corpus callosum agenesia, bladder 
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exstrophy, cerebellar hypoplasia, duodenal atresia) and the detection rates of many 
structural defects fall in between these figures (e.g. CHDs, omphalocele, limb reduction, 
spina bifida, atrhrogryposis). In general, approximately half of major structural defects can 
be detected at the time of first-trimester US screening (Rossi & Prefumo 2013).    
  
2.3.4.3 Congenital heart defects 
Fetuses with increased NT have a higher prevalence of CHDs than the general population 
and the prevalence of CHDs increases by increasing NT (Bahado-Singh et al. 2005; Bilardo 
et al. 1998; Clur et al. 2008; Galindo et al. 2003; Ghi et al. 2001; Hafner E et al. 2003; Hyett 
et al. 1997a, Hyett et al. 1999; Makrydimas, Sotiriadis & Ioannidis 2003; Mavrides et al. 
2001; McAuliffe et al. 2004;  Michailidis & Economides 2001; Orvos et al. 2002; Zosmer 
et al. 1999). The prevalence of CHDs in the general population is 3.7 - 6/1000 (Ferencz et 
al. 1985; Hoffman & Kaplan 2002). Among fetuses with increased NT ≥ 3.5 mm, the 
prevalence of CHDs varies from 23.3/1000 (Bahado-Singh et al. 2005) to 107/1000 
(McAuliffe et al. 2004) in different studies. All types of CHDs are detected after increased 
NT (Atzei et al. 2005; Clur et al. 2008; Simpson & Sharland 2000). These observations rose 
high expectations in using increased NT as a screening tool for CHDs. Unfortunately, NT 
is only moderately effective as a screening tool for CHDs, the detection rates ranging from 
4.2 - 15% (Jouannic et al. 2011; Mavrides et al. 2001; Muller et al. 2007) to 40 - 50% (Hyett 
et al. 1999; Orvos et al. 2002; Sananes et al. 2010) for the cut-off of 3.5 mm. Pooled data 
showed 37.5% detection rate of CHDs with a false-positive rate of 4.9% with a cut-off of 
95th percentile/2.5mm (Hyett 2004). In a meta-analysis focusing on those CHDs which 
would benefit from prenatal screening the estimated detection rate was 52% with a 5% 
false-positive rate using a cut-off of 1.7 MoM. (95% CI 42-71) (Wald et al. 2008). A recent 
review concluded a sensitivity value of 44% and a specificity of 94% with 95th percentile 
cut-off and sensitivity of 20% and specificity of 99% with 99th percentile cut-off using 
increased NT as a screening method for major CHDs (Sotiriadis et al. 2013). Increased NT 
in combination with abnormal ductus venosus flow and tricuspid regurgitation is associated 
with CHDs even in euploid fetuses (Clur, Ottenkamp & Bilardo 2009). In experienced 
centres, an early fetal echocardiography at < 16 weeks of gestation is 78.5% sensitive and 
there is a 74.5% concordance between the early and mid-trimester echogardiogram. 
However, an early diagnosis often needs to be confirmed later in the pregnancy and some 
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CHDs become evident later in gestation (e.g. ventricular septal defect, aortic coarctation) 
(Clur & Bilardo 2014; Huggon et al. 2002; Lopes et al. 2003). 
 
2.3.4.4 Genetic syndromes 
Increased NT implies numerous genetic syndromes (Souka et al. 2005). Of these Noonan 
syndrome has the strongest association with increased NT (Pergament et al. 2011). 
Congenital adrenal hyperplasia, 22q11 deletion syndrome (DiGeorge syndrome), spinal 
muscular atrophy, Stickler syndrome, Jarcho-Levin syndrome, artrogryposis, fetal akinesia 
deformation sequence, body stalk anomaly, Zellweger syndrome, and Smith-Lemli-Opiz 
syndrome have been noticed together with increased NT (Hyett et al. 1997b; Souka et al. 
1998 & 2005). Since the prevalence of these syndromes generally is very low, it is very 
difficult to prove the correlation with statistical methods.  
 
2.3.4.5 Cystic hygroma 
Cystic hygroma is defined as an enlarged NT space extending along the entire length of the 
fetus. Septations are clearly visible in cystic hygroma. The outcome of fetuses with cystic 
hygroma is adverse: 50 - 60% are aneuploid (Graesslin et al. 2007; Kharrat et al. 2006; 
Malone et al. 2005; Scholl et al. 2012) and of the euploid, up to 29-34% have major 
structural defects (Malone et al. 2005; Scholl et al. 2012).  Normal pediatric outcome has 
been reported in only 15-17% (Kharrat et al. 2006; Malone et al. 2005; Scholl et al. 2012). 
Turner syndrome is found in 12% of fetuses having cystic hygroma (Scholl et al. 2012). 
CHDs are more common among fetuses with cystic hygroma compared to those with 
increased NT without it (Sananes et al. 2010).  
 
 2.3.5 Pregnancy outcomes  
 
Favourable pregnancy outcome of euploid fetuses with increased NT decreases by 
increasing NT. The outcome is favourable in approximately 90% of the fetuses with NT ≥ 
95th percentile – 3.5mm (Bilardo et al. 2007) and 20-30% in fetuses with NT ≥ 6.5mm 
(Bilardo et al. 2007; Souka et al. 2001). This can be explained by the increasing rate of 
MCs, IUFDs, and structural defects by increasing NT (Bilardo et al. 2007; Michailidis & 
Economides 2001, Souka et al. 2001). The pregnancy outcome of euploid fetuses with 
increased NT followed by normal second-trimester screening is favourable in 96-98% 
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(Bilardo et al. 2007; Souka et al. 2001). However, in cases of persisting nuchal edema at 
the time of second-trimester screening adverse outcome is observed in up to 18% of the 
euploid fetuses (Souka et al. 2001). Screening for maternal infection (Cytomegalovirus, 
Parvovirus, and Syphilis) is warranted in such cases (Sebire et al. 1997a). 
 
2.3.6 Neurodevelopmental outcome 
 
Concern has been expressed about the later neurodevelopmental outcome of fetuses with 
increased NT. Data interpretation about this subject is difficult for several reasons:  
- There is no generally accepted definition for neurodevelopmental disorder. 
- Malfunction of the brain causes neurodevelopmental disorders that manifest as 
problems of cognition, behavior, and communication at a later age. For this 
reason, a long follow-up time is required. 
- Children are flexible and the learning processes are individual. A child having 
a neurodevelopmental problem at a younger age may not present such problems 
later.   
- Diagnosis of a neurodevelopmental disorder usually requires repeated 
examinations and follow-up in special health care. 
- Parental questionnaires may be unreliable as they may give biased information. 
Several studies report on the neurodevelopmental outcome of euploid children after 
increased NT in the first-trimester screening (Bilardo et al. 2007; Brady et al. 1998; Hiippala 
et al. 2001; Miltoft et al. 2012; Mula et al. 2012; Schou et al. 2009; Senat et al. 2002; Senat 
et al. 2007) with significant heterogeneity among studies in the NT cut-off levels, follow-
up times, and methodology. The rate of neurodevelopmental impairment has varied from 
0% (Maymon et al. 1998) to 7.4% (Senat et al. 2002). According to the most recent reports, 
the neurodevelopmental outcome of euploid children with increased NT in the first-
trimester screening is favourable at the age of two years (Miltoft et al. 2012; Mula et al. 
2012). In the studies with control groups no differences in the neurodevelopmental 
outcomes between those with increased NT and those with normal NT could be detected 
(Brady et al. 1998; Miltoft et al. 2012; Senat et al. 2007). 
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2.3.7 The significance of fetal gender 
 
The results of previous research about the impact of fetal gender in NT thickness are not 
conclusive. Several studies with large cohorts (n = 2637-12189) have shown that male 
fetuses with normal outcome have thicker NT than female fetuses (the female NT being 
0.98 MoM of the male NT) (Lam et al. 2001; Larsen et al. 2002; Rode et al. 2011; Spencer 
et al. 2000b; Timmerman, Pajkrt & Bilardo 2009). However, one study with a smaller cohort 
(n = 1325) failed to show this difference (Yaron et al. 2001). In one study the NT thicknesses 
of fetuses with trisomy 21 did not differ by gender (Cowans et al. 2009), while another 
study with a smaller cohort reported on a similar gender difference among healthy fetuses 
(Spencer et al. 2000b). The reason for the difference between the genders is not known, but 
accelerated growth and later maturation of male fetuses, especially of the cardiac system 
(Clur et al. 2011; Prefumo, Venturini & de Biasio 2003) have been thought to affect the NT 
thickness. The difference of the NT thickness between the genders is small (0.05-0.1mm) 
and thus the clinical implication is limited, especially because of intraobserver variation and 
limitations in the US resolution have larger impact on the measurement. At 12 weeks the 
accuracy of fetal gender determination by US examination is 87% (Hsiao et al. 2008), and 
therefore the impact of the gender difference on parental counselling is very limited. The 
only study about the relationship of gender and increased NT is from the Netherlands from 
2009 (Timmerman, Pajkrt & Bilardo 2009). A comparison of fetuses (n= 7072) with normal 
NT to those with increased NT (n=636) gave a better outcome for males compared to 
females in the group of increased NT (RR for adverse outcome 0.72 for male gender and 
even 0.47 for male gender when NT was ≥ 95th percentile and < 99th percentile). A small 
degree of NT enlargement in a male fetus was taken to be a normal finding in their study. 
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3 AIMS OF THE STUDY 
 
The principal goal of this study is to provide data for high-quality parental counselling when 
the NT is increased in the first-trimester screening. In order to achieve this goal, three 
different aspects are considered with specific aims: 
 
1. To find out the pregnancy outcomes after increased fetal NT in the first-
trimester screening (Study I). 
 
2. To detect the long-term neurodevelopmental outcome and the long-term 
overall outcome of euploid children with increased NT in the first-
trimester screening and a normal findings in the second-trimester 
screening US (Studies II and IV). 
 
3. To estimate the impact of fetal gender on the pregnancy outcome and on 
the long-term outcomes of children born after increased first-trimester 
fetal NT (Study III). 
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4 MATERIALS AND METHODS 
 
This is a retrospective cohort study performed in a single referral institution. It includes all 
singleton pregnancies with increased NT in the first-trimester screening referred to the DFM 
in HUH during the period between January 2002 and December 2007. DFM is a tertiary 
referral centre providing health care for approximately 1.5 million inhabitants of the area. 
Until 1.3.2004 the institutional cut-off level for increased NT in HUH was 3.0 mm, 
thereafter the institutional 95th percentile cut-off levels based on internal material were used 
(Table 2). 
 
Table 2. Fetal crown-rump length (CRL) dependent 95th percentile cut-off levels of 
nuchal translucency (NT) thickness used at Helsinki University Hospital during 2004 – 
2007. 
 
CRL (mm) NT ≥ mm CRL (mm) NT ≥ mm 
34-36 1.7 51-54 2.3 
37-39 1.8 55-58 2.4 
40-41 1.9 59-63 2.5 
42-44 2.0 64-69 2.6 
45-47 2.1 70-80 2.7 
48-50 2.2   
 
 
During the study period first-trimester screening based on the NT measurement without 
maternal biochemistry for trisomy 21 was offered to all pregnant women booked at the local 
antenatal clinics. In Finland more than 99% of pregnant women attend the national antenatal 
clinics where care and screening are free of charge. Scans were performed by trained and 
experienced midwives or physicians working at the maternity units. The highest NT value 
was used in the risk assessment as recommended (Nicolaides, Heath & Cicero 2002). 
Fetuses with cystic hygroma and hydrops were included in the study, since the same 
diagnostic work-up procedures were offered in these cases.  
After an abnormal screening result parents were offered counselling and an option of 
invasive karyotyping by CVS or AC at the DFM. Further counselling by a perinatologist 
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and a geneticist was offered after an abnormal karyotyping result or if structural defects 
were diagnosed in the US examination. 
Second-trimester US screening for structural defects was offered to all ongoing pregnancies 
at 18 – 22 gestational weeks. If the karyotype was normal and the initial NT < 3.0 mm, the 
second US screening was offered within the normal screening protocol and it was performed 
by a trained midwife. If the initial NT was ≥ 3.0 mm, the second screening was performed 
by a perinatologist at the DFM. Further examination by a pediatric cardiologist was 
available whenever there was any suspicion of a CHD.  
All liveborns were examined by a pediatrician before discharge from the delivery hospital; 
this is the normal policy for all children in Finland. If prenatal karyotyping was not 
performed, the karyotype was assumed to be normal, if the newborn showed no dysmorphic 
features and was apparently healthy. The follow-up time of the children was counted in full 
years, from the year of birth until the end of year 2012, or emigration abroad, or death in 
some cases.  
MC was defined as a spontaneous fetal loss at < 22 + 0 gestational weeks and stillbirth as 
a spontaneous fetal loss later during the pregnancy. Stillbirth and neonatal death during the 
first week of life were registered as perinatal deaths according to the Finnish Birth Register 
guidelines. 
The study materials of the four studies are presented in Table 3.  
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A register search until the end of the year 2012 was performed from three different 
independent national sources: National Institute for Health and Welfare (THL), the Social 
Insurance Institute of Finland, Insurance of Medical Unit (SIIF) and Causes of Death 
Statistics. The data collected from the registers is described in Table 4. All health care units 
in Finland are obligated to report certain information to THL, which keeps several registers. 
The statistics are reliable as only less than 0.1% of births are missing from the Medical Birth 
Register. The Register of Congenital Malformations actively collects information about the 
malformations from Medical Birth Register, Hospital Discharge Register, Causes of Death 
Statistics, hospitals, cytogenetic laboratories, and health care professionals.  
Every disabled Finnish child is entitled to a disability allowance from the SIIF, if the 
disability is severe enough. The allowance must be applied for by a standard form filled in 
by the physician responsible for the treatment of the child. The allowance is granted if the 
SIIFs physician agrees with the referring physician. Three different rates of disability 
allowance are used: basic, middle, and high. The rate depends on the strain the child’s 
impairment causes on the family. Basic allowance is payable for a child whose impairment 
needs weekly treatment or rehabilitation. Middle allowance is payable when the impairment 
causes a more severe strain on the family, and highest allowance when the treatment and 
rehabilitation causes an extreme, around the clock, need of care and strain on the family. 
All cases of death are reported to the Causes of Death Statistics in Finland, and recorded by 
Statistics Finland. We received data about all cases of death in the population under study. 
A child was considered to have neurodevelopmental impairment if there was an 
International Classification of Diseases (ICD-10) diagnosis of the group F (mental and 
behavioural diseases) or G (diseases of the neurological system) and a disability allowance 
from the SIIF was granted. The neurodevelopmental impairment was considered severe, if 
the disability allowance rate was medium or high; it was considered mild, if the rate was 
basic. All ICD-10 diagnoses attained from the registers were checked from the individual 
medical charts by the author. The data received from the Medical Birth Register was used 
to exclude children with confounding factors considering the neurodevelopment in Study 
II: prematurity (< 37+0 weeks), asphyxia (umbilical artery pH ≤ 7.05 or ICD-10 diagnosis 
of asphyxia), small for date (SFD) or large for date (LFD) children (birth weight under or 
over two standard deviations for gestational age), or prenatally missed CHD (transposition 
of great arteries) with postnatal low oxygenation.  
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Structural defects were classified as major or minor using the classification of the European 
surveillance of congenital anomalies (Eurocat 2013; Eurocat 2014). Children with health 
problems not likely to be related to the increased NT (asthma, allergy, malignancies, 
diabetes mellitus, epilepsy, migraine, juvenile polyarthritis) were counted together with the 
healthy ones. Children with a minimal structural defect (ankyloglossia, preauricular fistula 
not needing operation, subluxation of the hip not needing any treatment, naevus flammeus 
without any anomalies of the vascular system) were also classified as healthy. 
The study was approved by HUH Ethical Committee (Dnro 421/E9/07, 10 January 2008 
and 79/13/03/03/2013, 27 February 2013) and by THL (Dnro THL/1715/5.05.00/2012, 21 
March 2013), SIIF (Kela 69/522/2012, 15 May 2013), and Statistics Finland (TK-53-1474-
12, 7 January 2013). 
 
4.1 Statistical analyses 
 
Continuous variables were presented as mean (range, ± standard deviation), or n (%) with 
odds ratio (OR) and 95% confidence interval (95% CI). Continuous variables were analysed 
by Mann Whitney U-test. The Chi-square test was used in exploring the relationship of 
categorical variables. The tests were carried out by using Predictive Analysis Software 19.0 
for Windows (SPSS Inc, Chigaco, IL, USA). The level of statistical significance was 
defined as p < 0.05.  
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5 RESULTS 
 
We were able to identify altogether 1110 pregnancies with increased NT during the study 
period. In 47 (4%) cases the pregnancy data were insufficient and these had to be excluded. 
Pregnancy outcome data was available for 1063 pregnancies and the long-term outcome 
data for 763 euploid children. The mean NT thickness in the first-trimester US screening 
was 3.7 mm (1.9 – 14.7, ± 1.7), with mean gestational age 12+5 weeks (10 – 14, ± 6 days) 
(Figure 5). The mean maternal age was 31 years (17 – 47, ± 5.5).   
 
 
Figure 5. Nuchal translucency (NT) thickness (mm) and gestational age in a cohort of 1063 singleton 
pregnancies with increased NT in the first-trimester screening.  
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5.1 Pregnancy outcomes 
 
Of the 1063 pregnancies, 209 (20%) ended in TOP, 36 (3%) in MC, four (0.4%) in stillbirth 
and three (0.3%) infants died in the early neonatal period. There were 811 (76%) children 
born alive and surviving the perinatal period. Of these, 740 (91%) were healthy at the time 
of discharge from the delivery hospital, whereas 71 (9%) had health problems; of these 44 
had a normal karyotype. (Figure 6)  
 
Figure 6. Pregnancy outcomes after increased nuchal translucency (NT). TOP, termination of pregnancy; MC, 
miscarriage; PD perinatal death. 
 
Among the 209 pregnancies ending in TOP, 31 (15%) fetuses were euploid, 176 (84%) had 
chromosomal abnormalities, and the karyotyping failed in two (1%). A structural defect or 
syndrome was observed in 25/31 of the euploid fetuses, in six fetuses hydrops was the only 
abnormal finding after TOP in pathological examination. The cases with structural defects 
and syndromes are included in Tables 5-7. The mean maternal age in the TOP group was 
34 years (17 – 47, ± 5.5), mean NT was 5.2 mm (2.1 – 13.8, ± 2.6), mean gestational age at 
the first-trimester US screening was 12+4 weeks (10 – 14, ± 6 days), and the mean gestation 
at the TOP was 15 weeks (11 – 22, ± 2.0).  TOP was performed without prenatal karyotyping 
in 34 cases. In this group, 19 chromosomal abnormalities were detected, and in 13 the 
karyotype was normal and in two the karyotyping failed. There were severe structural 
defects in 11 of the euploid fetuses.  
There were 771 euploid fetuses with normal findings in the second-trimester screening US: 
one was stillborn (no reason other than asphyxia was found in autopsy), three had an 
antenatal diagnosis after the second-trimester screening US (one of each: multiple 
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ventricular septal defects, multicystic kidney, and supraventricular tachycardia), and 27 had 
health problems before discharge from the delivery hospital (Tables 5-7, Figure 6). At the 
time of discharge from the delivery hospital 96% (740/771) of euploid fetuses with 
increased NT in the first-trimester screening and normal findings in the second-trimester 
US screening were healthy (Figure 7).  
 
Figure 7. Adverse short-term outcomes of euploid fetuses with increased nuchal translucency (NT) in the first-
trimester screening and normal findings in the second-trimester ultrasound screening. 
 
5.2 Structural defects  
 
Structural defects were detected in 87 of euploid fetuses or children: there were 34 CHDs 
(Table 5) and 53 other structural defects (Table 6). Major structural defects were detected 
in 7.2% (60/834) of the euploid fetuses. The rate of CHDs among the euploid fetuses was 
4.1%. Of the 223 euploid fetuses with NT ≥ 3.5 mm, 14 (6.3%) had a CHD.  
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5.3 Syndromes and genetic disorders 
 
Syndromes or genetic disorders were diagnosed in 34 (4.1%) of the euploid fetuses (Table 
7). Chromosomal microarray was not used in prenatal diagnosis at the time of the study. 
Later, during the follow-up of the children, chromosomal microarray was performed in a 
few cases with neurodevelopmental impairment and/or suspected genetic syndromes (Table 
8). Targeted DNA testing revealed abnormal findings in five children with clinically 
suspected syndromes/diseases (Beckwith-Wiedemann syndrome, Mulibrey-Nanism, 
Noonan syndrome, Duchenne muscular dystrophy, CHARGE syndrome) after a normal 
conventional karyotype analysis. 
 
5.4 Chromosomal abnormalities 
 
There were 831 (78%) fetuses in the whole cohort of 1063 with normal karyotype, 227 
(21%) had chromosomal abnormalities, of which three minor abnormalities were detected 
later during the follow-up when further diagnostic work-up was performed due to 
neurodevelopmental impairment and/or other health problems (118-p deletion mosaicism, 
microdeletion 1p36, microdeletion 12q21.31q22). The karyotype was unknown due to 
failed analysis after MC or TOP in five (1%) cases. CVS or AC was performed in 926 
(87%) of patients. The percentage of fetuses with normal karyotype decreased by 
increasing NT: 93% among fetuses with NT 95th percentile – 2.9 mm had normal 
karyotype compared to 25% of fetuses with NT ≥ 6.0 mm (Table 9). The mean NT for 
fetuses with normal karyotype was 3.3 mm (1.9 -12.4, ± 1.0), for those with trisomy 21 
4.7 mm (2.4 – 13.8, ± 2.1), trisomy 18 5.3 mm (2.5-11.2, ± 2.3), trisomy 13 5.2 mm (2.6 -
11.0, ± 2.7), 45,X 7.8 mm (2.1 – 14.7, ± 3.3), and for those with other chromosomal 
abnormalities 4.2 mm (2.4 – 10.1, ± 1.8) (Figure 8).  
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Figure 8. Nuchal translucency (NT) thicknesses in fetuses with increased NT in the first-trimester screening: 
chromosomally normal fetuses and fetuses with different chromosomal abnormalities.  
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5.5 Long-term outcomes 
 
From the 771 euploid children with normal findings in the second-trimester US screening, 
one was stillborn and seven were lost for follow-up. Complete data were available for 763 
children. The mean follow-up time was 6.5 years (0.2 – 10, ± 1.8).  
 
5.5.1 Long-term neurodevelopmental outcome 
 
When assessing the long-term neurodevelopmental outcome of euploid children with 
normal findings in the second-trimester US screening, children with neurodevelopmental 
confounding factors (asphyxia, SFD, LFD, prematurity, CHD with low oxygenation 
postnatally) were excluded. Of the 70 (9%) excluded cases, eight (11%) had genetic 
syndromes, minor chromosomal abnormalities, or neurodevelopmental disorders (Table 
10). Two cases were excluded due to death not related to the increased NT at two months’ 
age (sudden infant death syndrome and carbon monoxide poisoning). The mean follow-up 
time of the 691 children remaining in the cohort after exclusions was 6.5 years (4-10, ± 0.6). 
Of these, 29 (4.2%) had neurodevelopmental impairment, and in 12 (1.7%) children it was 
severe (Table 11). The mean NT of children with severe neurodevelopmental impairment 
was 3.9 mm (2.8 - 8.0, ± 1.5). This was higher than the mean NT of healthy children and 
those with only minor neurodevelopmental problems, 3.2 mm (1.7 - 8.4 ± 0.7) (p = 0.03) 
(Figure 9). The NT thicknesses of healthy children compared to those having any 
neurodevelopmental problems did not differ (p = 0.6). The neurodevelopmental outcome 
among children having fetal NT < 3.5 mm and those with NT ≥ 3.5 mm did not differ (p = 
0.7 for all neurodevelopmental disorders and p = 0.2 for severe neurodevelopmental 
disorders).  
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Table 10. Children with confounding neurodevelopmental factors and increased fetal nuchal 
translucency (NT) ruled out from the analysis of long-term neurodevelopmental outcome. 
NT 
(mm) 
Reason for exclusion 
(gestation/birth 
weight/Apgar score) 
Diagnosis 
Disability allowance 
Age at diagnosis 
3.3 LFD  
(36+6 /3520g/9) 
Beckwith-Wiedemann syndrome  
Middle allowance 
2 months 
6.4 LFD  
(37+5/4290g/10) 
Noonan syndrome. 
No allowance 
3 years 
2.7 Prematurity  
(31+6/1800g/9) 
Mixed developmental disorders Middle 
allowance 
4 years 
3.6 Asphyxia  
(UA pH 7.00) 
(41+6/3810g/8)  
18-p deletion mosaicism. 
No allowance 
1 year 
2.5 SFD, asphyxia  
(UA pH 7.00) 
(37+0/2220g/1)  
Microdeletion 1p36, VSD  
Middle allowance 
VSD at birth, 
microdeletion at 2 
years 
3.7 SFD, asphyxia 
(38+2/2015g/1) 
Facio-auriculo-vertebral-spectrum 
syndrome, VSD multiplex, ASD 
secundum 
Basic allowance 
VSD at birth, 
syndrome  at 3 
years 
8.0 SFD  
(40+2/2255g/9) 
Mulibrey-Nanism, exitus at 3 years  
No allowance 
VSD at birth, M-N 
at 9 months 
2.7 CHD, low oxygenation 
postnatally 
TGA and expressive language disorder  
Basic allowance 
TGA at birth, 
language disorder 
at 5 years 
ASD, atrial septal defect; UA,umbilical artery; CHD, congenital heart defect; LFD large for date; SFD, small 
for date; M-N, Mulibrey-Nanism; TGA, transposition of great arteries; VSD, ventricular septal defect 
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Figure 9. Nuchal translucency (NT) thickness of euploid children with increased fetal NT in the first-trimester 
screening: NT thickness of children with severe neurodevelopmental impairment and mild or no impairment. 
 
 
 
5.5.2 Long-term overall outcome 
 
Of the 771 euploid children with normal second-trimester US screening findings one was 
stillborn, 30 children were known to be unhealthy at the time of discharge from the delivery 
hospital, and seven were lost for follow-up. During the follow-up, additional structural 
defects, genetic disorders and syndromes, or neurodevelopmental impairment were 
diagnosed in 64 cases (see Tables 5 - 7, 10, 11). There were 14 children with a diagnosis of 
more than one category. The outcomes of euploid fetuses with normal second-trimester US 
screening result are presented in Figure 10. 
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Figure 10. Long-term over-all outcome of euploid children with increased fetal nuchal translucency (NT) in 
the first-trimester screening and normal findings in the second-trimester ultrasound screening.  
 
The percentage of favourable outcome after increased fetal NT and normal findings in the 
second-trimester US screening was 88%. When only major health impairment (major 
structural defects, genetic syndromes, and severe neurodevelopmental impairment) were 
considered, 54 (7%) of children were unhealthy and the long-term favourable outcome for 
euploid children with increased fetal NT and normal second-trimester US screening was 
93%. The favourable outcome was 92-95% in different NT thickness groups up to 5.9 mm 
(Table 12). The NT thickness, mean 3.5 mm (2.4 - 8.4 ± 1.3), of the children with major 
health impairment did not differ from the healthy group and those with minor impairment, 
mean 3.2 mm (1.7 - 8.3 ± 0.7) (p = 0.09). Favourable outcome became less likely by 
increasing NT, the difference became significant at NT thickness ≥ 4.8 mm (p = 0.048, OR 
3.1, 95% CI; 1.2–8.8). 
 
Table 12. The long-term outcomes during the follow-up period of 6.5 years (mean) of 
euploid children with increased nuchal translucency (NT) thickness in the first-
trimester screening and normal second-trimester ultrasound screening findings.  
NT n (%) Favourable n (%) Adverse* n (%) 
95th** – 2.9 mm 291 (38) 277 (95) 14 (5) 
3.0 - 3.9 mm 384 (51) 354 (92) 30 (8) 
4.0 – 4.9 mm 63 (8) 58 (92) 5 (8) 
5.0 - 5.9 mm 17 (2) 16 (94) 1 (6) 
≥ 6.0 mm 8 (1) 4 (50) 4 (50) 
All 763 709 (93) 54 (7) 
*major structural defects, major neurodevelopmental impairment, syndromes and 
genetic disorders. **95th percentile 
 64 
 
5.6 The effect of fetal gender 
 
There were 1011 fetuses with known pregnancy outcome and normal sex-chromosomes. 
The mean NT was 3.6 mm (1.7 - 13.8, ± 1.4), the mean gestation at the time of the screening 
was 12+6 weeks (10+0 - 14+0, ± 6 days). There were 600 males and 411 females: the male to 
female ratio was 1.46:1. This ratio decreased by increasing NT: it was 1.6:1 when the NT 
was ≥ 95th percentile – 3.9 mm and 1:1 when the NT was ≥ 4.0 mm. The pregnancy 
outcomes according to gender in this cohort are presented in Table 13. The pregnancy 
outcome of males was better compared to females (p = 0.049). There were more 
aneuploidies among the females (21%) than among the males (16%) (p = 0.04, OR 1.4, 95% 
CI 1.03 – 2.0). Among euploid fetuses there was no difference between the genders in the 
pregnancy outcome (p = 0.6). The long-term outcome between the genders was equal (p = 
0.9) (Table 14). 
 
Table 13. Pregnancy outcome by gender in fetuses with increased nuchal 
translucency in the first-trimester screening. 
 n Favourable outcome 
n (%) 
Adverse outcome 
n (%) 
All 1011 740 (73) 271 (27) 
All males 600 453 (75)* 147 (25) 
All females 411 287 (70)* 124 (30) 
All euploids 829 740 (89) 89 (11) 
Euploid males 505 453 (90) 52 (10) 
Euploid females 324 287 (89) 37 (11) 
*p = 0.049 
  
 
Table 14. Long-term outcome by gender in euploid children with increased 
nuchal translucency in the first-trimester screening and normal findings in the 
second-trimester screening. 
 n (%) Favourable 
outcome n (%) 
Adverse outcome n 
(%)* 
All 763 (100) 709 (93) 54 (7) 
Males 465 (61) 431 (93) 34 (7) 
Females 298 (39) 278 (93) 20 (7) 
*Major structural defects, major neurodevelopmental impairment, genetic 
disorders and syndromes. 
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6 DISCUSSION 
 
The results of this study showed that after a diagnosis of increased NT in the first-trimester 
screening the proportion of favourable pregnancy outcome decreased by increasing NT. In 
euploid fetuses with increased NT in the first-trimester screening and normal findings in the 
second-trimester US screening the pregnancy outcome was favourable in 96% and the long-
term outcome in 93%. During the follow-up of 6.5 years (mean), severe 
neurodevelopmental impairment was detected in 1.7% of children. Adverse outcome (major 
structural defects, severe neurodevelopmental impairment, or genetic disorders) were 
detected in 7% of euploid children with increased fetal NT in the first trimester and normal 
findings in the second-trimester US screening. The pregnancy outcome of male fetuses was 
better compared to females with increased NT. This was explained by the higher incidence 
of chromosomal abnormalities among the female fetuses. Among euploid fetuses no gender 
difference could be verified in the pregnancy outcome or in the long-term outcome. 
 
6.1 Pregnancy outcomes 
 
Studies considering the pregnancy outcomes and increased NT are summarized in Table 
15. There is substantial heterogeneity among the studies. Different NT cut-offs are used, 
study cohorts are derived from general population or from high-risk populations, and many 
cohorts are fairly small and only five studies have more than 500 cases. The overall adverse 
pregnancy outcome among euploid fetuses varied from 6% (Souka 1998) to 41% (Dane et 
al. 2008). In the largest studies the percentage of adverse outcome was 6 – 23% (Bilardo et 
al. 2007; Mangione et al. 2001; Michailidis and Economides 2001; Pandya et al. 1995; Senat 
et al. 2007; Souka et al. 1998; Souka et al. 2001; Study I).  The 11% rate of adverse 
pregnancy outcome in our study is in line with these previous studies and gives a solid basis 
for parental counselling. 
 
There are only three studies reporting on the outcome of euploid fetuses after increased NT 
and normal second-trimester US screening. Favourable outcome was recorded in 96-98% 
of cases (Bilardo et al. 2007; Souka et al. 2001; Study I). However, in the first study (Souka 
et al. 2001), the follow-up time of the children was not reported, and in the second study 
the follow-up time was only two years on average (Bilardo et al. 2007). In our first study 
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the follow-up time was until the discharge from the delivery hospital (Study I) and thus it 
did not allow most of the neurodevelopmental disorders to be included. Our more recent 
study (Study IV) of the overall outcome took into account the neurodevelopmental 
impairment and later diagnosed structural defects and genetic disorders and showed that 
during 6.5 years of follow-up, favorable outcome occurred in 93%. This fact made us 
conclude that the high rates of favourable outcome after normal second-trimester US 
screening in earlier studies are slightly misleading.  
 
6.2 Structural defects  
 
The 7.2% rate of major structural defects detected among the euploid fetuses in this study 
is in line with the previous large studies reporting rates of 3 – 11% (Bilardo et al. 2007; 
Mangione et al. 2001; Michailidis & Economides 2001; Pandya et al. 1995; Souka et al. 
1998; Souka et al. 2001). An exceptionally high rate (30%) of structural defects was 
reported in one study (Senat et al. 2002). The NT cut-off in this study was higher than in 
the others, 4 mm, which might explain the difference. In our study the mean NT was 3.6 
mm and most of the fetuses (76%) had a NT ≤ 4mm. Most of the major structural defects 
in our cohort (Study I, Study IV) were CHDs, which is in keeping with previous studies 
(Bilardo et al. 2007; Souka et al. 1998; Souka et al. 1998).  
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6.3 Congenital heart defects 
 
The prevalence of CHDs in our study among all euploid fetuses was 41/1000 and 63/1000 
for those with NT ≥ 3.5 mm. This is in line with the previously reported prevalences 
(Bahado-Singh et al. 2005; Bilardo et al. 1998; Clur et al. 2008; Galindo et al. 2003; Ghi et 
al. 2001; Hafner et al. 2003; Hyett et al. 1997a & 1999; Makrydimas, Sotiriadis & Ioannidis 
2003; Mavrides et al. 2001; McAuliffe et al. 2004; Michailidis & Economides 2001; Orvos 
et al. 2002; Zosmer et al. 1999). The definition of major CHD varies among studies since, 
unfortunately, there is no universal definition for major CHD. Whereas several studies 
classify major CHDs as those warranting interventions or those likely to be lethal without 
operative treatment, we relied on the Eurocat classification in defining the severity of 
anomalies. According to its criteria almost all CHDs are classified as major (Eurocat 2013) 
and this leads to overestimation of clinically relevant CHDs. If only those CHDs where 
intervention (operation, catheterization) were included, the rates would be 22/1000 (18/831) 
and 36/1000 (8/223), for all euploid fetuses and for those with NT ≥ 3.5 mm, respectively. 
The prevalence of major CHDs in previous studies for fetuses with NT ≥ 3.5 mm has varied 
between 23.3/1000 (Bahado-Singh et al. 2005) and 106.7/1000 (McAuliffe et al. 2004). Our 
results are near the lower rates of previous publications and reflect that our cohort was 
derived from general screening, as in the study of Bahado-Singh et al., and not from a 
selection with a high background risk.  Although using the Eurocat classification may lead 
to overestimation in CHDs, its advantages of replicability and clarity make it feasible and 
recommendable. All types of CHDs are related to increased NT and this was also shown in 
our study. Of the clinically relevant CHDs warranting interventions 67% (10/15) were 
detected at the time of the second-trimester US screening. There were 18 CHDs requiring 
intervention, but three were not amenable for detection at the time of second-trimester US 
(two cases with patent ductus arteriosus and one case with secondary atrioventricular septal 
defect). It is important to carefully examine the heart of a fetus with a history of increased 
NT and specialized echocardiography by pediatric cardiologist should be performed with a 
low threshold.  
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6.4 Syndromes and genetic disorders 
 
A wide variety of syndromes and genetic disorders were diagnosed in our cohort, and the 
results were in agreement with previous studies (Bilardo et al. 2010; Souka et al. 2005). 
Antenatal diagnosis was reached in 17/18 of those syndromes and genetic disorders that 
could have been diagnosed before discharge from the delivery hospital; only one case of 
CHARGE multianomaly syndrome passed undetected. However, during follow-up, severe 
syndromes (Mulibrey-nanism, Septo-optic dysplasia, Duchenne muscular dystrophy among 
other less severe syndromes) were diagnosed. These children did not show any distinct 
symptoms at the time of discharge from the delivery hospital. Antenatal diagnosis of these 
syndromes might be possible in the future as knowledge of the etiology and the use of 
chromosomal microarray is growing. A link between increased NT and Noonan syndrome 
has been shown (Pergament et al. 2011). Prenatal testing poses some problems, since 
several mutations are associated with Noonan syndrome, but not all are known yet. Three 
cases of Noonan syndrome were clinically diagnosed in our cohort as well. The genetic 
testing did not reveal this syndrome in two of the three children, but in one case the genetic 
mutation was verified. The clinical outcome of Noonan syndrome varies greatly and 
antenatal genetic testing for this syndrome raises ethical questions, since it is not possible 
to predict the severity of the disease in an affected fetus.  
 
6.5 Chromosomal abnormalities 
 
Two large studies about chromosomal abnormalities among fetuses with increased NT 
included 11315 (Kagan et al. 2006) and 1015 fetuses (Pandya et al. 1995) with NT cut-off 
of  ≥ 95th percentile and ≥ 3 mm, respectively. In both studies 19% of fetuses had abnormal 
karyotype. Our results with 22% of fetuses having abnormal karyotype are in keeping with 
these studies, as are the percentages in different NT thickness groups and the distributions 
of different chromosomal abnormalities.  
A smaller percentage of chromosomal abnormalities, 10%, was reported in a study with 
4767 fetuses with NT ≥ 95th percentile (Snijders et al. 1998), and higher percentages 33-
34% have been reported in smaller studies from the Netherlands with 74 (Bilardo et al. 
1998) and 675 fetuses (Bilardo et al. 2007). There is no obvious reason (mean maternal age 
31) for the smaller rate in the study by Snijders et al. The higher rates in the studies by 
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Bilardo et al. may be due to the population selection: there was no general screening 
program in the Netherlands at the time of the studies and thus the participating women had 
increased background risks (e.g. were older, had family history, a permanent disease) for 
an adverse outcome.  
The results in different NT thickness groups in our study are also very similar to those of 
Kagan et al. who reported an aneuploidy rate ranging from 7%, when the NT was 95th centile 
– 3.4mm, reaching up to 75%, when the NT was ≥ 6.5 mm. The distribution of different 
chromosomal abnormalities in our study is in agreement with the previous reports: of the 
fetuses with chromosomal abnormalities approximately 50% had trisomy 21, 25% trisomy 
13 or 18, and 10% Turner syndrome (Kagan et al. 2006; Pandya et al. 1995). The mean NTs 
of different chromosomal abnormalities in the present study were similar to those reported 
previously (Wright et al. 2008). 
The uptake of invasive procedures was 87% in our study. The karyotypes of those with no 
invasive testing were examined after TOP, MC, or after the birth in children with clinical 
suspicion of chromosomal abnormality. If the child was apparently healthy, the karyotype 
was assumed to be normal and not examined. Since the follow-up time in our study is long 
and the information is gathered from several different sources, the assumption of a normal 
karyotype is likely to be true.  The motives for not opting for invasive procedures are 
simplified in two categories: those proceeding to TOP because severe structural defects or 
fetal hydrops and those continuing the pregnancy and not daring to take any procedure- 
related risks (Kobelka et al. 2009). After TOP or MC the chromosomal analysis failed in 
five cases due to culture failure. This possibility should be taken into account when 
counselling the parents since chromosomal abnormality as an explanation for the US 
finding might affect the prognosis of a subsequent pregnancy. Thus, even in cases where 
TOP is opted for due to an US abnormality, CVS or AC should be considered prior to TOP 
to avoid the situation where the karyotype remains unknown. 
There are several studies about the advantage of using chromosomal microarray after a 
normal QF-PCR result excluding the most common aneuploidies when the NT is ≥ 3.5 mm. 
Some studies did not show any pathologic CNVs (Huang et al. 2014; Schou et al. 2009) 
whereas in other studies 1-13% of fetuses had pathologic CNVs when analyzed with aCGH 
(Leung et al. 2011; Lund et al. 2015; Scott et al. 2013). Among fetuses with structural 
defects, 6% had pathologic CNVs compared to 0.4% among fetuses with false-positive 
trisomy 21 screening result but no structural defects (Wapner et al. 2012). Two studies about 
aCGH after increased NT ≥ 3.5mm and normal QF-PCR result showed CNVs in 5.7 -13% 
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of fetuses (Lund et al. 2014; Pan et al. 2016). Chromosomal microarray was not used in our 
clinic at the time of this study. Retrospectively, we recorded whether chromosomal 
microarray had been performed after a syndrome had been clinically diagnosed/suspected 
or in the etiological work-up of neurodevelopmental impairment. The use of chromosomal 
microarray in HUH Children’s hospital in such circumstances was lower than expected, 
since in only five out of 12 cases with severe neurodevelopmental impairment chromosomal 
microarray had been performed. Of the children excluded from the neurodevelopmental 
long-term analysis due to confounding factors (SFD, LFD, asphyxia, prematurity) 7% had 
abnormal findings on microarray (Mulibrey-Nanism, Beckwith-Wiedemann syndrome, 
microdeletion (1)(p36), deletion-mosaicism, Noonan syndrome). These children comprise 
a high-risk group and this should be taken into account if additional problems occur during 
the pregnancy or childbirth after increased NT.  More studies about the use of chromosomal 
microarray in fetuses with increased NT are needed, but according to the available data, 
chromosomal microarray should be offered whenever there is an antenatal diagnosis of a 
structural defect.  
 
6.6 Long-term outcomes 
 
Studies reporting the neurodevelopmental outcome after increased NT are summarized in 
Table 16. To our best knowledge, our study has the longest follow-up time and one of the 
largest cohorts. There is a great deal of heterogeneity among previous studies in the cohort 
size, methodology, NT cut-off, follow-up time, and also in the definition of 
neurodevelopmental impairment, which is not simple. Many studies are performed at least 
partly by parental questionnaire or interview (Bilardo et al. 2007; Brady et al. 1998; 
Maymon et al. 2000; Schou et al. 2009; van Vugt, Tinnemans & van Zalen-Sprock 1998), 
which might bias the results since parents are not objective in assessing their child’s 
development. Most studies did not have a control group and those containing a control 
group show no difference between the groups in their neurodevelopment (Brady et al. 1998; 
Miltoft et al. 2012; Senat et al. 2007). The rates of neurodevelopmental impairment in these 
studies varied from 0% to 13%. In our study the rate of neurodevelopmental impairment 
was 4.2% and of severe neurodevelopmental impairment 1.7 %. The prevalence of 
emotional, developmental, or behavioural disorders lasting for more than 12 months and 
warranting treatment or counselling among American children of ages 0 – 17 years is 5% 
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(Blanchard, Gurka & Blackman). Approximately 2% of Finnish children under 17 years of 
age receive disability allowance for neurodevelopmental disorders (Kelan 
vammaisetuustilasto 2014b, ´Disability allowance statistics Finland`). According to this we 
conclude that the neurodevelopmental outcome of euploid children after increased fetal NT 
does not differ from the background population, although a long-term follow-up study with 
a large cohort and a control group would be desirable.    
Our study is the only one that excludes pregnancies from the final analysis with 
confounding factors (preterm delivery, perinatal asphyxia, SFD and LFD) that may 
influence the neurodevelopmental outcome from the final analysis. The overall rate of 
neurodevelopmental problems, genetic syndromes and minor chromosomal abnormalities 
was 10% among these children.  
Only few major additional structural defects and genetic disorders were detected after an 
apparently healthy child was discharged from the delivery hospital (study IV). The policy 
of all newborns to be examined by a pediatrician before discharge from the delivery hospital 
in Finland seems to be appropriate and justified in detecting major defects.  
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6.7 The effect of fetal gender 
 
Generally male fetuses seem to have poorer pregnancy outcome than female fetuses (Di 
Renzo et al. 2007), but a Dutch study reporting the outcome of fetuses with increased NT 
yielded contrary results with male fetuses having better prognosis compared to females. 
Results of this study implied that male fetuses with only slightly increased NT (95th 
percentile – 3.4 mm) had twice better chances of uneventful pregnancy outcome compared 
to females. The authors speculated that a slight increase in male fetuses’ NT might be a 
normal phenomenon due to the accelerated growth of the fetus or the slower maturation of 
males compared to females (Timmerman, Pajkrt & Bilardo 2009). The Dutch study 
comprised 581 fetuses whereas ours is based on much larger data of 1011 fetuses (Study 
III). Our results do not support their explanation. We observed that the pregnancy outcome 
of males was better compared to females, but this was explained by the higher incidence of 
chromosomal abnormalities among the females. We suggest that the NT measurement 
might be a better screening tool for chromosomal abnormalities in female fetuses compared 
to males, although it was not possible to prove this in our material since we do not have the 
data of false negative cases in our screening. Determination of fetal gender is possible by 
US, chromosome analysis or by analysing the cell-free fetal DNA in the mother’s blood 
sample (NIPT). Ultrasonographic accuracy for gender determination improves by 
increasing fetal age. At 12 weeks gender determination accuracy was 87% and at 13 weeks 
it was 96% (Hsiao et al. 2008). NT measurement performance is best before 13 weeks. 
Given the accuracy of 87% or less for gender determination at this point of time, it is not 
rational to determine the fetal gender by ultrasonography at the same time as the NT is 
measured, as the gender determination at the time of first-trimester US screening is possible 
but not definitive (Colmant et al. 2013; Hsiao et al. 2008). Our observation that the gender 
of euploid fetuses does not affect the outcome is reassuring. Fetal gender does not need to 
be taken into account in counselling the parents, the only exception being suspicion of 
Turner syndrome whenever a fetus has an extremely large NT.  
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6.8 Clinical relevance of nuchal translucency at present and in future 
 
The methods of prenatal screening are being developed with the introduction of new 
screening strategies and techniques leading to the improvement of the previously used 
strategies. Introduction of NIPT created high expectations because of its better accuracy 
compared to other screening methods for aneuploidies, but the high cost of this technique 
prevents its use in general screening. Even if the price of NIPT decreased to a financially 
affordable level, which would make it a preferable screening method in general use, it would 
only screen for the chromosomal abnormalities and the advantages of the first-trimester US 
examination (location, number, viability, anatomy of the fetus) would be missed. The 
information from the first-trimester US examination is of great clinical importance as it has 
several obvious advantages: high risk pregnancies (e.g. of twins) receive adequate follow-
up, TOP can be offered when fetuses with extremely severe structural defects (e.g. 
anencephaly) are diagnosed.  Thus it is not likely, that the first-trimester US examination 
will be abandoned, even if NIPT is adopted for trisomy screening. Evidence shows that 
CHDs are more likely to be detected in high-risk compared to low-risk population (Rasiah 
et al. 2006). Since increased NT is associated with structural defects, especially CHDs and 
genetic disorders, its measurement has an important role in the selection of pregnancies with 
high-risk to whom expert anomaly scan and the most precise (and expensive) genetic 
analysis (aCGH) are offered (Figure 11).  
 
  
6.9 Management of pregnancies with increased nuchal translucency 
 
NT measurement is an essential part of combined screening. There is evidence that waiting 
for the serum marker results in pregnancies with NT ≥ 3mm does not bring any additional 
benefit in aneuploidy screening (Comstock et al. 2006). However, in cases with a NT 
between ≥ 95th percentile and 3 mm, the serum markers define the individual risk and the 
need for further diagnostic work-up.  
Fetuses with increased NT comprise a high-risk group. Since NIPT is more expensive than 
combined screening and aCGH is more expensive than QF-PCR or conventional 
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karyotyping, each society, with the locally given resources, has to make their own 
recommendations in patient selection to these tests. 
Our proposal of pregnancy management after increased NT is shown in Figure 11. This is 
the current policy at the DFM in HUH. After any abnormal result information about 
different available options should be offered to the parents. Multidisciplinary counselling, 
in utero treatment when possible, pregnancy follow-up, and timing and delivery in the third-
level prenatal centre with high quality neonatal care should be the standard procedure. 
Continuous education should be offered to the screeners and special attention should be 
paid to the examination of the fetal heart as its screening is particularly challenging due to 
the complex structure.  
        
6.10 Strengths  
 
The major strength of our study is the large cohort with a long follow-up time of 6.5 years 
(mean). The results are reliable since special attention was paid to confirm the short- and 
long-term diagnoses by searching the individual medical charts in all cases. Every diagnosis 
retrieved from the registers was double checked from the hospital databases. Additionally, 
several confounding factors were taken into account in the neurodevelopmental assessment. 
In order to ensure valid results in Study III, fetuses with abnormal sex-chromosomes were 
excluded.  
 
6.11  Limitations 
 
A control group would have given further strength to our study, but it was not technically 
possible to gather such a group for several reasons. Since many of the syndromes and 
structural defects diagnosed among fetuses with increased NT are extremely rare, the 
control group should have been very large to reveal any real difference. At the time of this 
study from 2002 to 2007 screening results were not computerized and thus it would not 
have been feasible to collect an adequate-sized and scientifically valid control group large 
enough with normal NT thicknesses. Even though many national registers are available in 
Finland, there is no national fetal screening register, which would ease the research. 
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7 CONCLUSIONS 
 
Increased fetal NT is associated with chromosomal abnormalities, structural defects, genetic 
syndromes, and adverse pregnancy outcomes. 
 
1. An adverse pregnancy outcome becomes more likely by increasing NT. 
One in five fetuses with increased NT in the first-trimester screening has 
chromosomal abnormalities, and structural defects or genetic syndromes 
are detected in one in ten of the euploid fetuses with increased NT. 
 
2. The neurodevelopmental outcome of euploid children with increased 
fetal NT seems to be favourable. Severe neurodevelopmental 
impairment was detected in 1.2% of children with increased fetal NT 
with a follow-up time of 6.5 years. Major health impairment (major 
structural defects, severe neurodevelopmental impairment, or genetic 
syndromes) was detected in 7% of euploid children with increased fetal 
NT and normal findings in the second-trimester screening. 
 
3. Male fetuses with increased NT have better pregnancy outcome than 
female fetuses, but there are more chromosomal abnormalities among 
the females. The pregnancy outcome or the long-term outcome of 
euploid fetuses do not differ by gender. 
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